Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
ZALTRAP: renal dosing versus proteinuria-based treatment modification
This source only - not a merged recommendation
What matters first
Product: Adult IV ZALTRAP with its labeled oncology regimen. Not ophthalmic aflibercept; partner chemotherapy requires separate review.
Renal action / finding
Baseline no adjustment does not override proteinuria hold rules.
Evidence or dialysis limit
Severe-impairment PK sample was small; no dialysis regimen established.
Monitoring / application
Monitor urine protein and apply the separate toxicity thresholds.
Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.
Product / population
Adult IV ZALTRAP with its labeled oncology regimen. Not ophthalmic aflibercept; partner chemotherapy requires separate review.
Renal measure
Baseline renal categories/CrCl; proteinuria uses g per 24 hours
Source revision
05/2025
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Severe-impairment PK sample was small; no dialysis regimen established.
Sections 8.6, 12.3, 2.2 and 5.7
Sections 8.6, 12.3, 2.2 and 5.7
Situation
Source-specific guidance
Baseline renal impairment
No renal dose adjustment recommended; severe data limited.
Proteinuria >=2 g/24 hours
Hold until <2 g/24 hours. Recurrence: hold, then reduce to 2 mg/kg.
Nephrotic syndrome or thrombotic microangiopathy
Discontinue.
Read the retained text before reformatting
No baseline renal dose adjustment is recommended, but only five patients with CrCl below 30 mL/min contributed to the cited PK analysis. Hold for proteinuria at least 2 g/24 hours; resume after it falls below 2 g/24 hours. Recurrent proteinuria requires another hold and subsequent permanent reduction to 2 mg/kg. Discontinue for nephrotic syndrome or thrombotic microangiopathy. Monitor urine protein. These findings do not establish dialysis dosing or replace the separate renal review of FOLFIRI components.
Source revision: 05/2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
ZALTRAP: renal dosing versus proteinuria-based treatment modification
Source retrieved 2026-11-07 - confirm current applicability
No dialysis regimen established in selected content
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Baseline no-adjustment guidance does not cancel proteinuria holds
Renal categories describe baseline dosing, whereas proteinuria, nephrotic syndrome and thrombotic microangiopathy trigger separate modifications.
How to use this: Assess both baseline kidney function and treatment-emergent proteinuria; do not interchange with ocular aflibercept.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
ZALTRAP: renal dosing versus proteinuria-based treatment modification
Adult IV ZALTRAP with its labeled oncology regimen. Not ophthalmic aflibercept; partner chemotherapy requires separate review.
Method: Baseline renal categories/CrCl; proteinuria uses g per 24 hours
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
An RX mirror and its underlying label are not independent clinical confirmations.
DailyMed / product prescribing information · Adult IV ZALTRAP with its labeled oncology regimen. Not ophthalmic aflibercept; partner chemotherapy requires separate review.
Renal method: Baseline renal categories/CrCl; proteinuria uses g per 24 hours Source date: 05/2025 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Severe-impairment PK sample was small; no dialysis regimen established.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Sections 8.6, 12.3, 2.2 and 5.7
Sections 8.6, 12.3, 2.2 and 5.7
Situation
Source-specific guidance
Baseline renal impairment
No renal dose adjustment recommended; severe data limited.
Proteinuria >=2 g/24 hours
Hold until <2 g/24 hours. Recurrence: hold, then reduce to 2 mg/kg.
Nephrotic syndrome or thrombotic microangiopathy
Discontinue.
Read the retained text before reformatting
No baseline renal dose adjustment is recommended, but only five patients with CrCl below 30 mL/min contributed to the cited PK analysis. Hold for proteinuria at least 2 g/24 hours; resume after it falls below 2 g/24 hours. Recurrent proteinuria requires another hold and subsequent permanent reduction to 2 mg/kg. Discontinue for nephrotic syndrome or thrombotic microangiopathy. Monitor urine protein. These findings do not establish dialysis dosing or replace the separate renal review of FOLFIRI components.
RDM71-ziv-aflibercept-zaltrap-label-1 · Source locator: Sections 8.6, 12.3, 2.2 and 5.7
GlobalRPh RX List / label mirror · Adult IV ZALTRAP with its labeled oncology regimen. Not ophthalmic aflibercept; partner chemotherapy requires separate review.
Renal method: CrCl in mL/min; category-based PK analysis Source date: Not established in reviewed passage Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Confirm product, indication, renal measure and dialysis modality before applying.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Selected renal sections
The renal PK passage does not recommend baseline dose adjustment. The severe-impairment group was small. Do not interpret the passage as eliminating proteinuria precautions or establishing dialysis dosing.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
